Senti Biosciences (SNTI) has released an update to notify the public and investors about listing compliance status.
Senti Biosciences, Inc. has successfully transferred its common stock listing from The Nasdaq Global Market to The Nasdaq Capital Market and obtained an additional 180-day period to meet Nasdaq’s minimum $1.00 bid price requirement. The company is working to remedy its bid price deficiency by August 5, 2024, to avoid delisting and may consider a reverse stock split as a solution. Trading under the symbol “SNTI,” the move to The Nasdaq Capital Market is not anticipated to affect the stock’s trading activity on Nasdaq.
For further insights into SNTI stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
